-+ 0.00%
-+ 0.00%
-+ 0.00%

LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38

Benzinga·08/20/2026 15:43:51
Listen to the news
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.